Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

(2010) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Drosophila Histone Deacetylase 6 Protects Dopaminergic Neurons against α-Synuclein Toxicity by Promoting Inclusion Formation

(2010) Guiping Du et al.   MOLECULAR BIOLOGY OF THE CELL

Impaired Function of HDAC6 Slows Down Axonal Growth and Interferes with Axon Initial Segment Development

(2010) Mónica Tapia et al.   PLoS One

Paclitaxel Directly Binds to Bcl-2 and Functionally Mimics Activity of Nur77

(2009) C. Ferlini et al.   CANCER RESEARCH

Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice

(2009) D H Hwang et al.   GENE THERAPY

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

(2009) Axel Hauschild et al.   JOURNAL OF CLINICAL ONCOLOGY

OPTIC NEUROPATHY IN PATIENTS WITH GLIOBLASTOMA RECEIVING BEVACIZUMAB

(2009) J. H. Sherman et al.   NEUROLOGY

Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib

(2009) Adam D. Lipworth et al.   ONCOLOGY

HDAC6 Is Required for Epidermal Growth Factor-induced β-Catenin Nuclear Localization

(2008) Yu Li et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation

(2008) R. B. Parmigiani et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA